---
id: esc-acute-coronary-syndromes-2024
title: "ESC 2024 Guidelines for the Management of Acute Coronary Syndromes"
short_title: "ESC ACS 2024"

organization: European Society of Cardiology
collaborators: null
country: Global (Europe-led)
url: https://www.escardio.org/Guidelines
doi: null
pmid: null
open_access: true

specialty: cardiology
guideline_type: clinical-practice
evidence_system: ESC GRADE
conditions:
  - acute coronary syndrome
  - NSTEMI
  - unstable angina
  - STEMI
tags:
  - PCI
  - DAPT
  - troponin
  - antiplatelet
  - reperfusion

publication_date: 2024-08-01
previous_version_date: 2020-08-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 ESC guideline on the diagnosis and management of acute coronary syndromes (ACS), including STEMI and NSTE-ACS.

## Key Recommendations

### Diagnosis
- **High-Sensitivity Troponin (hs-cTn)**: Measure at presentation and 1-2 hours (0h/1h or 0h/2h algorithm) for rapid rule-in/rule-out.
- **ECG**: Obtain within 10 minutes of first medical contact.

### STEMI Management
- **Primary PCI**: Preferred reperfusion strategy if available within 120 minutes of first medical contact.
- **Fibrinolysis**: If PCI not available within 120 min, give within 10 minutes and transfer for rescue PCI if needed.
- **Radial Access**: Preferred over femoral for PCI.

### NSTE-ACS Management
- **Risk Stratification**: GRACE score. Very high-risk features (hemodynamic instability, refractory angina, arrhythmias, heart failure) require immediate invasive strategy (<2 hours).
- **High-Risk**: Invasive strategy within 24 hours.
- **Intermediate-to-Low Risk**: Invasive strategy within 72 hours or selective approach.

### Antithrombotic Therapy
- **Aspirin**: Loading dose (150-300 mg), then 75-100 mg daily lifelong.
- **P2Y12 Inhibitor**: Ticagrelor (preferred) or prasugrel for patients undergoing PCI; clopidogrel if bleeding risk high or on OAC.
- **DAPT Duration**: Default 12 months; shorten to 1-3 months + P2Y12 monotherapy if high bleeding risk.
- **Anticoagulation (Acute Phase)**: UFH, enoxaparin, or bivalirudin during PCI.

### Post-ACS Secondary Prevention
- High-intensity statin, ACEi/ARB, beta-blocker (post-MI with reduced LVEF), BP control, glycemic control, smoking cessation, cardiac rehab.
- Colchicine 0.5 mg daily may be considered for residual inflammatory risk.
